Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SCN1A | P35498 | 2/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | BRD1 | O95696 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928522 | 0.89 | CDK1 (0.48) | MCL1HSD11B1RXFP1SMN1; SMN2KMT2A | |
| SCHEMBL3930289 | 0.89 | SCN1A (0.48) | HSD11B1SMN1; SMN2SCN1ASCN5ASCN8A | |
| SCHEMBL3928251 | 0.89 | SMN1; SMN2 (0.46) | MCL1HSD11B1RXFP1SMN1; SMN2SCN1A | |
| SCHEMBL3937432 | 0.86 | SMN1; SMN2 (0.47) | MCL1HSD11B1RXFP1SMN1; SMN2KMT2A | |
| SCHEMBL3935238 | 0.85 | MCL1 (0.45) | MCL1HSD11B1RXFP1SMN1; SMN2CTSA | |
| SCHEMBL3923611 | 0.82 | SMN1; SMN2 (0.44) | MCL1HSD11B1RXFP1SMN1; SMN2KMT2A | |
| SCHEMBL3936865 | 0.81 | HSD11B1 (0.60) | MCL1HSD11B1RXFP1SCN1ASCN5A | |
| SCHEMBL3927444 | 0.81 | HSD11B1 (0.70) | HSD11B1ALDH1A1LMNAL3MBTL1PKM | |
| SCHEMBL4495590 | 0.80 | LMNA (0.50) | MCL1RXFP1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL3922924 | 0.80 | SMN1; SMN2 (0.65) | MCL1HSD11B1SMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101035762-B | Alkil-pyridines as 11-beta inhibitors for diabetes | HOFFMANN LA ROCHE | 2010-09-29 | — | — | CN | claimed |
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | claimed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| CN-101035762-B | Alkil-pyridines as 11-beta inhibitors for diabetes | HOFFMANN LA ROCHE | 2010-09-29 | — | — | CN | disclosed |
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | disclosed |
| CN-101035762-A | Alkil-pyridines as 11-beta inhibitors for diabetes | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | CN | disclosed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1799647-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037501-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD11B2 | MCL1 4015/4885HSD11B1 5/4885RXFP1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.